Who is sponsoring NCT05207904?

NCT05207904 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05207904?

Interventions in NCT05207904: Tislelizumab, paclitaxel, Carboplatin.

What condition does NCT05207904 study?

NCT05207904 studies Non-Small Cell Squamous Lung Cancer, Brain Metastases.

Is NCT05207904 still recruiting?

NCT05207904 is currently status unknown. Last updated 26 January 2022.

Last reviewed 2022-01-26 · How we verify

NCT05207904

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases

Status unknown Phase 2 Last updated 26 January 2022

What this trial tests

Phase 2 trial testing Tislelizumab, paclitaxel, Carboplatin in Non-Small Cell Squamous Lung Cancer in 41 participants. Status unknown.

Timeline

17 June 2021

Primary endpoint
30 December 2022

30 June 2023

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	17 June 2021
Primary completion	30 December 2022
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

Tislelizumab, paclitaxel, Carboplatin — full drug profile →

Conditions studied

Non-Small Cell Squamous Lung Cancer — all drugs for Non-Small Cell Squamous Lung Cancer →
Brain Metastases — all drugs for Brain Metastases →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Squamous Lung Cancer or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, single-arm, phase II clinical study to evaluate the efficacy and safety of Tislelizumab Plus Chemotherapy in patients with squamous NSCLC with brain metastases who had not previously received systemic therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tislelizumab, paclitaxel, Carboplatin

Trials testing the same drug.

NCT07131319 — SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC · Phase 2, PHASE3 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05207904 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 26 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing